Literature DB >> 30737462

Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.

D Allan Butterfield1, Barry Halliwell2.   

Abstract

Alzheimer disease (AD) is a major cause of age-related dementia. We do not fully understand AD aetiology and pathogenesis, but oxidative damage is a key component. The brain mostly uses glucose for energy, but in AD and amnestic mild cognitive impairment glucose metabolism is dramatically decreased, probably owing, at least in part, to oxidative damage to enzymes involved in glycolysis, the tricarboxylic acid cycle and ATP biosynthesis. Consequently, ATP-requiring processes for cognitive function are impaired, and synaptic dysfunction and neuronal death result, with ensuing thinning of key brain areas. We summarize current research on the interplay and sequence of these processes and suggest potential pharmacological interventions to retard AD progression.

Entities:  

Mesh:

Year:  2019        PMID: 30737462      PMCID: PMC9382875          DOI: 10.1038/s41583-019-0132-6

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   38.755


  121 in total

Review 1.  Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer's disease brain.

Authors:  Nona Abolhassani; Julio Leon; Zijing Sheng; Sugako Oka; Hideomi Hamasaki; Toru Iwaki; Yusaku Nakabeppu
Journal:  Mech Ageing Dev       Date:  2016-05-24       Impact factor: 5.432

2.  Oxidative Modification of miR-184 Enables It to Target Bcl-xL and Bcl-w.

Authors:  Jian-Xun Wang; Jie Gao; Su-Ling Ding; Kun Wang; Jian-Qin Jiao; Yin Wang; Teng Sun; Lu-Yu Zhou; Bo Long; Xiao-Jie Zhang; Qian Li; Jin-Ping Liu; Chang Feng; Jia Liu; Ying Gong; Zhixia Zhou; Pei-Feng Li
Journal:  Mol Cell       Date:  2015-05-28       Impact factor: 17.970

3.  Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial.

Authors:  Alina Solomon; Heidi Turunen; Tiia Ngandu; Markku Peltonen; Esko Levälahti; Seppo Helisalmi; Riitta Antikainen; Lars Bäckman; Tuomo Hänninen; Antti Jula; Tiina Laatikainen; Jenni Lehtisalo; Jaana Lindström; Teemu Paajanen; Satu Pajala; Anna Stigsdotter-Neely; Timo Strandberg; Jaakko Tuomilehto; Hilkka Soininen; Miia Kivipelto
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

4.  Vitamin E and donepezil for the treatment of mild cognitive impairment.

Authors:  Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal
Journal:  N Engl J Med       Date:  2005-04-13       Impact factor: 91.245

5.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 6.  Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2.

Authors:  Qiang Ma; Xiaoqing He
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

7.  Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease.

Authors:  D Allan Butterfield; H Fai Poon; Daret St Clair; Jeffery N Keller; William M Pierce; Jon B Klein; William R Markesbery
Journal:  Neurobiol Dis       Date:  2006-02-08       Impact factor: 5.996

8.  MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials.

Authors:  Adrià Casamitjana; Paula Petrone; Alan Tucholka; Carles Falcon; Stavros Skouras; José Luis Molinuevo; Verónica Vilaplana; Juan Domingo Gispert
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Glycation affects fibril formation of Aβ peptides.

Authors:  Alessandro Emendato; Giulia Milordini; Elsa Zacco; Alessandro Sicorello; Fabrizio Dal Piaz; Remo Guerrini; Richard Thorogate; Delia Picone; Annalisa Pastore
Journal:  J Biol Chem       Date:  2018-06-29       Impact factor: 5.157

10.  Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.

Authors:  Christopher M Weise; Kewei Chen; Yinghua Chen; Xiaoying Kuang; Cary R Savage; Eric M Reiman
Journal:  Neuroimage Clin       Date:  2018-07-17       Impact factor: 4.881

View more
  263 in total

1.  Late-onset epilepsy and 25-year cognitive change: The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Emily L Johnson; Gregory L Krauss; Keenan A Walker; Jason Brandt; Anna Kucharska-Newton; Thomas H Mosley; Sevil Yasar; Rebecca F Gottesman
Journal:  Epilepsia       Date:  2020-07-24       Impact factor: 5.864

2.  Alpha-lipoic acid ameliorates tauopathy-induced oxidative stress, apoptosis, and behavioral deficits through the balance of DIAP1/DrICE ratio and redox homeostasis: Age is a determinant factor.

Authors:  Elahe Zarini-Gakiye; Nima Sanadgol; Kazem Parivar; Gholamhassan Vaezi
Journal:  Metab Brain Dis       Date:  2021-02-06       Impact factor: 3.584

3.  Screening of Synthetic Isoxazolone Derivative Role in Alzheimer's Disease: Computational and Pharmacological Approach.

Authors:  Meissam Ali; Uzma Saleem; Fareeha Anwar; Muhammad Imran; Humaira Nadeem; Bashir Ahmad; Tahir Ali; Tariq Ismail
Journal:  Neurochem Res       Date:  2021-01-24       Impact factor: 3.996

4.  Middle aged turn point in parameters of oxidative stress and glucose catabolism in mouse cerebellum during lifespan: minor effects of every-other-day fasting.

Authors:  Maria M Bayliak; Nadia M Mosiichuk; Oksana M Sorochynska; Oksana V Kuzniak; Lesia O Sishchuk; Anastasiia O Hrushchenko; Alina O Semchuk; Taras V Pryimak; Yulia V Vasylyk; Dmytro V Gospodaryov; Kenneth B Storey; Olga Garaschuk; Volodymyr I Lushchak
Journal:  Biogerontology       Date:  2021-03-30       Impact factor: 4.277

Review 5.  Homocysteine and Gliotoxicity.

Authors:  Angela T S Wyse; Larissa Daniele Bobermin; Tiago Marcon Dos Santos; André Quincozes-Santos
Journal:  Neurotox Res       Date:  2021-03-30       Impact factor: 3.911

Review 6.  Effects of Peroxiredoxin 2 in Neurological Disorders: A Review of its Molecular Mechanisms.

Authors:  Jifei Liu; Gang Su; Juan Gao; Ye Tian; Xiaoyan Liu; Zhenchang Zhang
Journal:  Neurochem Res       Date:  2020-01-30       Impact factor: 3.996

7.  Metabolic Signatures of Life Span Regulated by Mating, Sex Peptide, and Mifepristone/RU486 in Female Drosophila melanogaster.

Authors:  Gary N Landis; Devon V Doherty; Chia-An Yen; Lu Wang; Yang Fan; Ina Wang; Jonah Vroegop; Tianyi Wang; Jimmy Wu; Palak Patel; Shinwoo Lee; Mina Abdelmesieh; Jie Shen; Daniel E L Promislow; Sean P Curran; John Tower
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-01-18       Impact factor: 6.053

Review 8.  Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders.

Authors:  Lucio G Costa; Toby B Cole; Khoi Dao; Yu-Chi Chang; Jacki Coburn; Jacqueline M Garrick
Journal:  Pharmacol Ther       Date:  2020-03-09       Impact factor: 12.310

Review 9.  Healthful aging mediated by inhibition of oxidative stress.

Authors:  Stephen F Vatner; Jie Zhang; Marko Oydanich; Tolga Berkman; Rotem Naftalovich; Dorothy E Vatner
Journal:  Ageing Res Rev       Date:  2020-10-19       Impact factor: 10.895

10.  Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.

Authors:  Gary E Gibson; José A Luchsinger; Rosanna Cirio; Huanlian Chen; Jessica Franchino-Elder; Joseph A Hirsch; Lucien Bettendorff; Zhengming Chen; Sarah A Flowers; Linda M Gerber; Thomas Grandville; Nicole Schupf; Hui Xu; Yaakov Stern; Christian Habeck; Barry Jordan; Pasquale Fonzetti
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.